IP Library Granted Patent US 9,260,694
Granted Patent B2
US 9,260,694 · App. 14/069,423 · Granted Feb 16, 2016

Generation of duck cell lines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,260,694
App. No.
14/069,423
Granted
Feb 16, 2016
Kind
B2
Abstract

The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from duck embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.

Claims (25)

1. A method of making a duck cell line comprising:

a) isolating a duck embryo around oviposition;

b) dissociating the embryo of step a) into cells;

c) seeding the dissociated cells of step b) in basal medium comprising insulin like growth factor 1 (IGF-1), ciliary neurotrophic factor (CNTF), animal serum, and a layer of feeder cells;

d) culturing the cells of step c) for at least one passage;

e) withdrawing the IGF-1 and CNTF from the culture of step d);

f) culturing the cells of step e) for at least one passage;

g) progressively withdrawing the feeder cells from the culture of step f);

h) culturing the cells of step g) for at least one passage;

i) progressively withdrawing the animal serum from the culture medium of step h) over several passages; and

j) adapting the cells of step i) to suspension culture conditions such that a duck cell line capable of proliferating in basal medium in the absence of exogenous growth factors, a feeder layer, and animal serum is obtained, wherein the duck cell line does not produce replication-competent endogenous retrovirus particles.

2. The process according to claim 1 , wherein the withdrawal of the growth factors IGF-1 and CNTF from the culture medium in step e) is performed simultaneously.

3. The process according to claim 1 , wherein said duck is a Pekin duck.

4. The process according to claim 1 , wherein said duck is a Muscovy duck.

5. The process according to claim 1 wherein said duck cell line has at least one of the following characteristics:

an endogenous telomerase activity,

a diameter of around 10 μm;

a population doubling time of around 30 hours or less at 37° C.; and

expresses one or more additional markers selected from the group consisting of alkaline phosphatase, SSEA-1, EMA-1, and ENS-1.

6. The process according to claim 1 , wherein said duck cell line is diploid.

7. The process according to claim 1 , wherein said duck cell line does not produce replication-competent endogenous avian leucosis virus (ALV-E) and/or endogenous avian virus (EAV) retrovirus particles.

8. The process according to claim 1 wherein the genome of said duck cell line does not contain proviral sequence of avian leucosis virus (ALV-E) and/or endogenous avian virus (EAV) susceptible to produce replication competent endogenous retroviral particles.

9. The method according to claim 1 , wherein the concentration of IGF-1 and CNTF in step c) each is 1 ng/ml.

10. The method according to claim 1 , wherein the concentration of animal serum in step c) is of 5% to 10%.

11. The method according to claim 1 , wherein the feeder cells in step c) are mitotically inactivated mouse fibroblast cells.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: VALNEVA AUSTRIA GMBH; VALNEVA SE; VALNEVA USA, INC.
Reel/Frame 073516/0522 →
SECURITY INTEREST Recorded Mar 4, 2020
From: VALNEVA SE; VALNEVA USA, INC.; VALNEVA AUSTRIA GMBH
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 052016/0745 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CHANGE OF NAME RECORDATION PREVIOUSLY RECORDED ON REEL 031607 FRAME 0481. ASSIGNOR(S) HEREBY CONFIRMS THE CONVEYING PARTY: VIVALIS RECEIVING PARTY: VALNEVA. Recorded Dec 12, 2013
From: VIVALIS
To: VALNEVA
Reel/Frame 031804/0451 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2013
From: GUEHENNEUX, FABIENNE; MOREAU, KARINE; ESNAULT, MAGALI; MEHTALI, MAJID
To: VIVALIS SA
Reel/Frame 031607/0429 →
CHANGE OF NAME Recorded Nov 15, 2013
From: VIVALIS SA
To: VALNEVA SE
Reel/Frame 031607/0481 →